IGF::OT::IGF R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

IGF::OT::IGF R

• 批准号: 8735452
• 负责人: N/A N/A
• 金额: $ 123.9万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-03-29 至 2014-03-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8735452
• 关键词: Age; Applied Research; Biological; Biological Markers; Biology; Blood Banks; Clinical; Contractor; Coronary heart disease; DNA Fingerprinting; DNA Methylation; Data; Development; Diagnostic; Event; Genes; Genetic Markers; Genomics; Mediating; Medical; Methodology; MicroRNAs; Pathway interactions; Phenotype; Plasma; Postmenopause; Resolution; Resources; Risk; Risk Factors; Technology; Testing; Woman; Women' s Health; age related; follow-up; genome wide association study; genome-wide; member; novel; prognostic; research and development

The contractor will take advantage of the existing large and unique Women's Health Initiative biological resource, which includes bio-banked blood from a large number of postmenopausal women who have been extensively phenotyped over a follow up period of up to 19 years. The contractor will carefully profile the DNA and plasma of coronary heart disease (CHD) cases (n ~ 1070), as well as an appropriate set of controls (n =~1070), using two complementary, but well-validated, genomic technologies at baseline. These high throughput genomic technologies are expected to generate high quality and high-resolution genome wide DNA methylation profiles as well as a comprehensive assessment of circulating microRNA levels in plasma. The contractor will then comprehensively analyze and integrate this genomic data with existing clinical, genetic, and biomarker data using state of the art statistical methodologies developed by members of the investigative team to identify genomic signatures and pathways relevant to CHD and its risk factors.

承包商将利用现有的大型且独特的妇女健康倡议生物资源，其中包括来自大量绝经后妇女的生物库血液，这些妇女在长达 19 年的随访期内进行了广泛的表型分析。承包商将使用两种互补但经过充分验证的基因组技术，仔细分析冠心病 (CHD) 病例 (n ~ 1070) 的 DNA 和血浆，以及一组适当的对照 (n = ~1070)。基线。这些高通量基因组技术预计将产生高质量、高分辨率的全基因组 DNA 甲基化谱，并对血浆中循环 microRNA 水平进行全面评估。然后，承包商将使用调查团队成员开发的最先进的统计方法，全面分析这些基因组数据并将其与现有的临床、遗传和生物标志物数据整合，以识别与 CHD 及其风险因素相关的基因组特征和途径。